PathAlert: The Next Generation of Rapid Testing. Easy. Compact. Safe.

Infectious disease outbreaks, such as COVID-19, Influenza, and Mpox, have profoundly impacted public health, with well over 500 million confirmed COVID-19 cases and 6 million deaths globally as of 2023¹. Meanwhile, Mpox cases surged to over 87,000 reported instances across 110 countries by early 2024².

Given the scale of these outbreaks, Micronbrane Medical introduces a simplified rapid testing method – PathAlert.

As an at-home or point-of-care rapid antigen test, PathAlert, is an indispensable tools for managing infectious diseases, providing immediate, cost-effective solutions for:

• Early and Accurate Diagnosis: Essential for reducing transmission by 56% in community settings³.
• Asymptomatic Carrier Screening: Up to 40% of infections may be asymptomatic but still contagious⁴. 
• Outbreak and Epidemic Monitoring: Accelerating response times can lower outbreak duration by 60%⁵.
• Travel and Entry Requirements: Supports containment strategies that enhance global health security.
• Treatment Efficacy: Provides actionable data for modifying patient management plans.
• Population and Workplace Surveillance: Testing can reduce the potential for larger-scale spread.

Complexity of Current Tests

Traditional rapid tests often involve multiple steps and components, increasing the risk of user error and contamination. This is problematic even in well-resourced settings and such errors could reduce test accuracy by up to 30%⁶.

The scarcity during periods of high demand, compounded by these reliability issues, undermines global efforts to detect, monitor, and contain infectious diseases effectively. 

A Single-Tube Solution from Micronbrane Medical

Unlike conventional rapid antigen tests with multiple components — such as swabs, buffer solutions, test strips, and tubes — PathAlert’s innovative design consolidates all testing steps into a single tube container, making it easy, compact, and safe.